obesity and endocrine disorders
DESCRIPTION
Obesity and Endocrine Disorders. Dr EM Selepe MBChB (Natal ) FCA(SA) 1 Military Hospital Thaba Tshwane. Obesity Definition. Excess of body fat sufficient to adversely affect health BMI is used as the surrogate marker Obesity is often defined in terms of the BMI - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/1.jpg)
1
Obesity and Endocrine Disorders
Dr EM SelepeMBChB(Natal) FCA(SA)
1 Military HospitalThaba Tshwane
![Page 2: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/2.jpg)
2
Obesity DefinitionO Excess of body fat sufficient to adversely
affect healthO BMI is used as the surrogate markerO Obesity is often defined in terms of the BMIO BMI does not take body build into
consideration and hence can be misleading in the presence of large muscle mass
O Fat distribution can be central (abdominal) or gluteo-femoral
O Central obesity has increased CVS risk factors
![Page 3: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/3.jpg)
3
Obesity AssessmentO BMI commonly usedO Waist to hip circumference ratio (WHR) can
be used or waist circumference aloneO Using BMI Wt/Ht squared (kg/m2)O WHO classification:1. <18,5 Underweight2. 18.5 - 24.9 Healthy3. 25 – 29.9 Overweight4. 30 – 39 Obese5. >40 Morbid Obesity
![Page 4: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/4.jpg)
4
Obesity Assessment“Cont”
O WHR (waist to hip ratio) O Male >1.0 Female >0.9O Waist circum Male> 103cm and
female >88 cmO Generally Waist < 100cm suggests
insulin resistance less likely in all sexes
![Page 5: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/5.jpg)
5
EpidemiologyO Rapid increase in both developed and
developing countriesO Prevalence on the increase stats from
the UK:1. 1980 6% of male and 8% of female2. 2000 increase to 21% and 21.4%
respectively3. Now 55% of population is
overweight or obese
![Page 6: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/6.jpg)
6
Clinical Problems O Psycho-social:1. Poor self esteem and image2. Depression3. WithdrawnO Medical:1. Gastro-oesophageal disease (GED)2. Secondary hypertension 3. Pulmonary hypertension4. Obstructive sleep apnoea (OSA)
![Page 7: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/7.jpg)
7
Anaesthetic PracticeO Upper airway1. Short neck, neck circumference
(male 42cm , female 41cm)2. Fat padding3. Large face- difficulty in holding
mask4. Mallampati grades 3 to 4,
Thyromental <6cm and sternomental < 12cm distance
5. Poor mouth opening
![Page 8: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/8.jpg)
8
Anaesthetic Practice“cont”
O Lower Airway:1. Poor lung compliance2. Increased airway resistance – chest bulk3. Higher peak airway pressures4. Pulmonary hypertension5. Decreased FRC leading to atelectasis and
hypoxia6. Increased abdominal pressure decreasing
the FRC ( Functional residual capacity )
![Page 9: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/9.jpg)
9
Anaesthetic Practice“Cont”
O Cardio-vascular System: 1. Secondary hypertension2. LVH, LAH leading to diastolic dysfunction3. RVH from pulmonary hypertension leading to
RHF4. Prone to DVT and pulmonary
thromboembolism – worsening pulmonary HPT
5. OSA leads to hypercapnia, sympathetic over stimulation worsening pulmonary and systemic hypertension .
![Page 10: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/10.jpg)
10
Anaesthetic practice “cont”
O GIT1. Gastric emptying- delyed,
potential full stomach2. Gastroeosophageal disease ( reflux)3. Associated disease ( hiatus hernia)4. Pressure on the splanchnic vessels
compromises liver perfusion.
![Page 11: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/11.jpg)
11
Anaesthetic considerations
Anticipated problems:O Airway managementO Potential full stomach ( starvation
period prolonged , ulcer prophylaxis )O Positioning of patient and intravenous
accessO Co - morbid diseasesO Possible post op high care or ICU – OSAO Deep venous thrombosis prophylaxis
![Page 12: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/12.jpg)
12
Endocrine Disorders( Metabolic Syndrome )
O Components 1. > Waist circumference2. Increased insulin resistance
( Diabetes mellitus)3. high LDL , decreased HDL4. Hypertension
![Page 13: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/13.jpg)
13
Diabetes mellitus and Obesity
O There is increased incidence of obesity and Diabetes
O Obese patients have increased resistance to insulin.
O Type 2 diabetes is common in these population
O Commonly on oral hypoglycaemics and or insulin.
![Page 14: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/14.jpg)
14
Diagnostic Criteria( WHO classification)
Venous plasma glucose ( mmol/l)
Normal Fasting2hrs post prandial
<6.0<7.8
diabetic Fasting2hr post prandial
>7.0>11.1
IGT(Impaired glucose tolerance)
Fasting 2hr post prandial
<7.0>7.8 – 11.1
IFG(Impaired fasting glucose)
Fasting 6.0 -6.9
![Page 15: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/15.jpg)
15
Aims of TreatmentO Sensitize receptors
(thiazolidinediones , Biguanides )O Increases the B cells production of
insulin( sulphonylurea , Biguanides , GLP I (glucagon like peptide 1) )
O Decrease absorption (alpha1 gylcosidase inhibitors)
O Insulin replacement
![Page 16: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/16.jpg)
16
Anaesthetic considerations
O Uncontrolled DM1. Dehydration (polyuria , polydypsia)2. Hyperosmolality (HONK)3. SepsisO Chronic DM1. Potential full stomach2. Autonomic and peripheral neuropathy3. Coronary artery diseases and HPT4. Kidney dysfunction/failure
![Page 17: Obesity and Endocrine Disorders](https://reader035.vdocuments.net/reader035/viewer/2022062315/56815dc7550346895dcbf419/html5/thumbnails/17.jpg)
17
Conclusion
O There is an accelerated prevalence of obesity and diabetes mellitus in South Africa and knowledge of the two entities is of essence as it is also part of metabolic syndrome.
O Airway management and the clinical dynamics of the two should be well appreciated.